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Adolescents experience disproportionately high rates of poor ART outcomes compared to adults despite prolonged use of
antiretroviral therapy in Southern African treatment programs, presenting a significant challenge to national attempts to meet
the UNAIDS 90-90-90 targets for 2020. This cohort study among adolescents aged 12–20 years accessing ART care at two urban
public-sector clinics in Johannesburg between September and November 2013 aimed to identify factors potentially associated with
poor attendance at clinic visits. Patients were followed up through routinemedical records to identifymissed visits (failing to attend
clinic within 30 days of scheduled visit date) up to 2 years after enrolment. We enrolled 126 adolescents on ART for a median of 6.3
years (IQR: 2.7–8.4). A total of 47 (38%) adolescents missed a scheduled visit within 24 months of enrolment. Older adolescents
(18–20 years) were more likely to miss a visit compared to adolescents aged 12–14 years (risk ratio (RR) = 1.72; 95% CI: 1.00–2.95).
Those who were identified to have difficulty in taking medication (RR = 1.57; 95% CI: 1.13–2.18) as a barrier to care were more
likely to miss a visit compared to adolescents who did not. Awareness of treatment fatigue, challenges to taking ART, and caregiver
difficulties is important when considering interventions to improve treatment outcomes among adolescents.
1. Introduction
Despite the incredible success of the large-scale public-sector
provision of antiretroviral therapy (ART) to HIV-infected
people in South Africa, failure to retain these patients on
long-term treatment threatens to undermine the massive
gains made since 2004 and remains one of the most critical
obstacles to achieving the UNAIDS 90-90-90 targets for 2020
which are intended to be a key milestone towards ending the
HIV epidemic by 2030 [1]. Adolescents have been identified
as vulnerable populations in need of prioritizing for adher-
ence to treatment [2, 3]. Globally, an estimated 2 million
adolescents (10–19 years) are living with HIV/AIDS, with
more than 80% of these from sub-Saharan Africa [4].
The escalating HIV-infected adolescent population, which is
attributed both to a high incidence of horizontally acquired
HIV and to long-term survival following perinatally acquired
HIV infection [5, 6],meanswe can expect to see large impacts
of this age group on national HIV treatment programs in the
coming years. The recognition of the particularly high risk
faced by adolescent girls and young women has seen initia-
tives such as PEPFAR’sDREAMS launch pilot projects involv-
ing evidence-based interventions intended to break the cycles
of HIV transmission in this group [7].
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Adolescence is a stage of transition from childhood to
adulthood, associated with specific challenges (including
puberty) and vulnerability (such as early sexual debut, HIV,
and STI acquisition). In addition, coping with the clinical and
psychosocial impacts of HIV imposes a substantial burden
on this vulnerable group [8–11]. HIV-infected adolescents
encounter several known economic barriers to accessingHIV
care such as cost of transport and distance to health facility
[12–14] and are often caught between pediatric and adult
services unable to address their special health needs which
include disclosure of HIV status, adherence support, stigma
and discrimination, sexual and reproductive health, mental
health care, and legal and social support [5, 15–17].
Scale-up of ART in South Africa over the past ten years
has been impressive with an estimated 3.4 million HIV-
infected individuals on ART by 2015 [18, 19]. However, ART
coverage for children in the region has historically been
considerably lower among children compared to adults (22%
versus 55%, resp., in 2010) [20] though coverage among
children has improved with USAID 2014 estimates indicating
that nearly 50% of children <15 years of age living with HIV
in South Africa are receiving ART [21]. Retention to ART is
one of the universal goals of HIV treatment programs, yet
there are several indications that adolescents are experiencing
disproportionately poor ART outcomes compared to adults
including higher rates of mortality, loss to follow-up, and
lower rates of virologic suppression compared to other age
categories [22–27], raising concern over the impact this group
may have on national efforts to achieve the 90-90-90 targets.
Despite this, there are no national level estimates of
adolescent retention in care or transfer across clinics and it
remains unclear as to which adolescents are most likely to
drop out of care in South Africa. Recent work using routine
laboratory data to create a national HIV cohort has demon-
strated the emergence of a youth treatment bulge, increasing
numbers of adolescents aged 10 years and older accessing
ART [28]. Given these figures and poor treatment outcomes
experienced by this group, understanding the potential
obstacles to adherence and retention in treatment programs
among adolescents is urgently warranted. This study aimed
to identify barriers and facilitators to remaining in and
adhering to the continuum of ART care among HIV-infected
adolescents in Johannesburg, South Africa. Identification of
such factors could enable HIV care programs in this setting
to target interventions most likely to reduce losses from ART
care among adolescent populations.
2. Materials and Methods
2.1. Study Design and Sites. This prospective cohort study
of HIV-infected adolescents accessing ART care was con-
ducted at two public-sector antiretroviral treatment facili-
ties in Johannesburg, South Africa. Both sites provide care
and treatment according to the South African Department
of Health National Antiretroviral Therapy Guidelines [12].
Under these guidelines, eligibility criteria for ART differed
by age of the child. Children eligible for ART included: (1)
all children <1 year of age; (2) children aged between 1 and 5
years with aWHOclinical stage 3 or 4 condition, a CD4 count
of 25% or less, or an absolute CD4 count <750 cells/mL; and
(3) children aged between 5 and 15 years with aWHO clinical
stage 3 or 4 condition or CD4 < 350 cells/𝜇L. Adolescents >15
years were eligible for treatment with (1) a CD4 count <200
irrespective of clinical stage, (2) a CD4 count <350 cells/mm3
(in the presence of TB or pregnancy), or (3) a WHO stage 4
condition or MDR/XDR TB irrespective of CD4 count.
At the time of the study, the Empilweni Clinic [29, 30], a
pediatric HIV care and treatment clinic based at the Rahima
MoosaMother andChildHospital (RMMCH), was caring for
approximately 400 adolescents aged 12–20 who were receiv-
ing (>80%) first-line antiretroviral treatment; the remainder
of the group were receiving either second treatment or lami-
vudine-based holding regimens. Standard first-line regimens
consisted of abacavir, lamivudine, and lopinavir/ritonavir for
those<3 years of age or 10 kg inweight and abacavir, lamivud-
ine, and efavirenz for those over 3 years of age and 10 kg. The
Themba Lethu Clinic (adult-based facility) is an outpatient
antiretroviral treatment facility based at Helen Joseph
Hospital, Johannesburg, Gauteng [31].The site’s patient popu-
lation is primarily adult (99% aged > 20 years) but at the time
of the study ART and treatment monitoring were provided
to approximately 80 adolescents. This includes a first-line
regimen of tenofovir with lamivudine or emtricitabine plus
either efavirenz or nevirapine.
2.2. Study Population. Eligible patients included HIV-
infected adolescents aged between 12 and 20 years of age who
were aware of their status and accessing ART treatment at
either Empilweni Clinic or Themba Lethu Clinic regardless
of duration of ART use. Identification of potentially eligible
participants occurred during routine HIV care visits between
September and November 2013 at specific clinic locations in
which patientswait for relevant services (i.e., HIV counseling,
doctor’s visit, and pharmacy drug collection). Eligible and
interested participants were provided with more detailed
information about the study in a separate counseling room
and individual consent (or participant assent plus parental or
legal guardian consent for adolescents < 18 years of age) was
obtained. This recruitment strategy proceeded in a consecu-
tive manner until the end of the enrolment period. All study
participants received a small financial compensation in the
form of a food voucher and parents or legal guardians who
returned to complete a scheduled study appointment with
an adolescent were also reimbursed for transport money.
2.3. Data Sources. Trained interviewers administered a struc-
tured questionnaire to each enrolled study participant.
Thoughmost questions were closed-ended, the questionnaire
also included pairwise ranking and some open-ended ques-
tions. Participant data from the questionnaire was entered
into a study database using CSPro software by trained data
capturers. Adolescents were asked whether they considered
several factors (related to caregivers, travel to clinic, psy-
chosocial elements, the health care facility, or the treatment
itself) as potential barriers to care during the interview.
Routinely collectedmedical record data (including clinic visit
dates, ART regimen history, and viral load results) were
extracted from electronic medical records maintained by
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each of the study sites and linked to participant questionnaire
data.
2.4. Study Variables and Analysis. The primary outcome was
defined as missing a scheduled ART drug collection visit
by more than 30 days. Several factors were investigated as
potential predictors of poor adherence. These included the
following: (1) demographic characteristics of the participant,
(2) socioeconomic features of the participant’s household, (3)
caregiver issues, and (4) problems with service delivery at the
treatment facility.
The characteristics of the study population were summa-
rized with descriptive statistics including simple proportions
for categorical variables and medians with interquartile
ranges for continuous variables. The overall frequency of
each of the factors reported during the interview as being
considered by the adolescent as a potential barrier to care is
presented. In addition, we present these frequencies stratified
by treatment facility and, by proxy, model of care (pediatric-
based compared to adult-based treatment sites). Next, asso-
ciations between each of the potential predictors andmissing
a clinic visit are estimated with crude risk ratios and 95%
confidence intervals. Estimates were also adjusted for age,
gender, mother as caregiver, and time on ART.
In secondary analysis, we defined prevalent unsuppressed
viral load at the time of study enrolment as having a VL >
400 copies/mL within 3 months prior to and 3 months after
the interviewdate.A log-binomial regressionmodelwas fitted
in order to determine risk factors associated with prevalent
unsuppressed viral load.
Previous work has demonstrated heterogeneity within
age substrata of adolescent populations in terms of treatment
outcomes [22, 25]. In order to evaluate differences in per-
ceived barriers to care by stage of adolescence, the analysis
of missed visits was further stratified by age category. Those
aged between 12 and 17 years at the time of study enrolment
were categorized as younger adolescents, while those aged 18–
20 years were categorized as older adolescents.
3. Results
In total, 206 adolescents were screened for potential enrol-
ment into the study. Of these, a total of 126 adolescents
(61%) were enrolled in the study with a median of 6.3 years
on ART (IQR 2.7–8.4): 19 adolescents from the adult-based
facility (Themba Lethu clinic) and 107 from the pediatric-
based facility (Empilweni Clinic). Of the remaining 80 not
enrolled, 41 (51%) did not meet eligibility criteria and 18
(23%) were unable to consent, as their legal guardian was
not present. Further 16 (8%) refused to participate (5 were
in a hurry, 4 were not interested, and 7 had no reason
given) and the remaining 5 were not enrolled for unknown
reasons. Similar overall proportions were enrolled at the
pediatric-based (27%) and adult-based (24%) facilities. The
demographic characteristics of the enrolled study partici-
pants are summarized in Table 1. Adolescents at the adult-
based care facility were older (median: 18 versus 15 years) and
predominantly female (68% versus 54%) and had received
fewer years of ART (median: 1.2 versus 6.8 years) than those at
the pediatric-based facility. Nearly three-quarters (73%) were
on first-line and the remaining quarter was on second-line
regimens at the time of study enrolment.
3.1. Potential Barriers to Care. Overall, the factor most
frequently reported during the interview as being considered
a potential barrier to care was long travelling distance to the
clinic (61% agreed it was a potential barrier to care), followed
by the possibility that the adolescent’s attendance at clinic
visits would be noticed by friends or members of the school
(33%), having an elderly caregiver (32%), high transport cost
of the trip to the clinic visit (32%,) and long queues to wait in
at the clinic (31%) (Table 2).
Though the factors most frequently reported to be poten-
tial barriers to care were the same for both the adult-based
site and pediatric-based site, the relative importance differed
slightly; having an elderly caregiver was reported as a poten-
tial barrier to care as frequently as long travelling distances
to the clinic among predominantly older adolescents at the
adult-based site, while it was the least frequently reported of
the five among those attending care at the pediatric facility.
Very few of the interviewed adolescents agreed that being
disinterested in care or not believing that ART helps would
be a barrier to care or that unfriendly health care workers
presented problems in accessing and remaining in care.
3.2. Adherence to Scheduled Visits. Adolescents completing
the questionnaire were then followed up passively through
routine medical record data for 24 months after study
enrolment.Of the 126 adolescents enrolled, 2 did not return to
their treatment clinic at all after the study interview. Among
the 124 that did attend at least one clinic visit after study
enrolment, 92 (74%) remained in care through to the end of
24months of follow-up, while 11 (9%) had been lost from care
and 21 (17%) had transferred to another heath care facility.
Overall, during the course of the 24months of follow-up, 38%
(𝑛 = 47) of the study participants missed a scheduled clinic
visit by 7 days or more. The median time to first missed visit
was 6.7 months (IQR 3.0–11.1) and 46.8% (𝑛 = 22) of visits
were missed within 6 months and further 34.0% (𝑛 = 16)
within a year after study enrolment.
Several demographic factors were associated with an
increased risk of missing a clinical visit after study enrolment
(Table 3). In crude analyses, among both of the older adoles-
cent categories (15–17 and 18–20), the proportions missing a
clinic visit were higher compared to the group of 12–14 years
(41% and 49%, resp., versus 28%). Overall, the results suggest
that older adolescents (15–20 years) weremore likely tomiss a
visit compared to those in the group of 12–14 years (risk ratio
(RR) = 1.59; 95% confidence interval (CI): 0.97–2.67) and
adolescents in the group of 18–20 years were at highest risk
of missing a clinic visit (RR: 1.72; 95% CI: 1.00–2.95) though
the estimates lacked precision and statistical significance.
Adolescents with their mother as their primary caregiver
were somewhat less likely to miss a visit (RR: 0.67; 95% CI:
0.43–1.06). When adolescents were asked if they agreed that
certain factors could be barriers to care, thosewho agreed that
potential barriers included having a caregiver with financial
difficulty (47% versus 36%), not having enough time for clinic
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Table 1: Demographics at study enrolment.
All (𝑁 = 126) TLC (𝑁 = 19) EC (𝑁 = 107)
Gender; 𝑛 (%)
Male 55 (43.7) 6 (31.6) 49 (45.8)
Female 71 (56.3) 13 (68.4) 58 (54.2)
Age (years); median (IQR) 15 (13–18) 18 (18-19) 15 (13–17)
Age group; 𝑛 (%)
12–14 54 (42.9) 2 (10.5) 52 (48.6)
15–17 34 (27.0) 2 (10.5) 32 (29.9)
18–20 38 (30.2) 15 (78.9) 23 (21.5)
Nationality; 𝑛 (%)
South African 120 (95.2) 18 (94.7) 102 (95.3)
Foreign 6 (4.8) 1 (5.3) 5 (4.7)
Highest school level; 𝑛 (%)
Secondary 48 (41.4) 9 (64.3) 39 (38.2)
Primary 68 (58.6) 5 (35.7) 63 (61.8)
Dwelling type; 𝑛 (%)
Informal 17 (13.5) 0 (0.0) 17 (15.9)
Formal 95 (75.4) 18 (94.7) 77 (72.0)
Care facility∗ 14 (11.1) 1 (5.3) 13 (12.1)
Number in household; median (IQR) 4 (3-6) 3 (2–6) 5 (3–7)
caregiver type; 𝑛 (%)
Mother 66 (52.4) 11 (57.9) 55 (51.4)
Granny 19 (15.1) 5 (26.3) 14 (13.1)
Aunt 20 (15.9) 1 (5.3) 19 (17.8)
Children’s home 13 (10.3) 1 (5.3) 12 (11.2)
Other 8 (6.3) 1 (5.3) 7 (6.5)
Caregiver employed; 𝑛 (%)
Yes 79 (62.7) 13 (68.4) 66 (61.7)
No 34 (27.0) 6 (31.6) 28 (26.2)
Time on ART (years); median (IQR) 6.3 (2.7–8.4) 1.2 (0.5–1.6) 6.8 (4.9–8.5)
∗Care facility included children’s home, hospice, or shelter.
visits (53% versus 36%), clinic visits being noticed by friends
or the school (45% versus 35%), and unfriendly health care
workers (75% versus 37%)more frequentlymissed a visit after
study enrolment than those who did not identify these as
barriers to care. Adolescents who agreed that having prob-
lems in taking the medication and becoming tired of taking
the medication were barriers to care were also more likely to
subsequently miss a visit (RR = 1.77; 95% CI: 1.14–2.74; and
RR = 1.77; 95% CI: 1.14–2.73, resp.). Estimates adjusted for
age, gender, mother as caregiver, and time on ART were less
precise but overall consistent with crude estimates (Table 3).
3.3. Prevalent Unsuppressed Viral Load. In total, 103 ado-
lescents had a recorded viral load measurement within the
defined prevalent virologic outcome window period (within
3 months prior to and 3 months after the interview date),
and, of these, 32 (31%) had a VL > 400 copies/mL. The
frequency of prevalent unsuppressed viral load differed by
several demographic factors (Table 4). A higher proportion of
those in both older adolescent categories (38% for 15–17 years
and 32% for 18–20 years) experienced unsuppressed viral load
at the time of study enrolment compared to those aged 12–14
years (26%). Prevalent unsuppressed viral load also differed
by gender (36%males versus 27% females). Higher frequency
of unsuppressed viral load was also noted among adolescents
who agreed that certain factors were obstacles to accessing or
remaining in care compared to those who did not agree. This
included having an ill caregiver (50% versus 30%), expensive
transport fees (39% versus 28%), and treatment fatigue (41%
versus 28%). Provider-related factors including long queues
and inconvenient clinic operating hours were not perceived
as barriers among those who did not have a suppressed VL.
3.4. Stratification by Age Category. As noted earlier, older
adolescents were more likely to miss a subsequent clinic visit
after study enrolment than either of the other age categories
AIDS Research and Treatment 5
Table 2: Frequency of reported factors, overall and by site.
All (𝑁 = 126) Adult-based facility (𝑁 = 19) Pediatric-based facility (𝑁 = 107)
Median number of factors (IQR) 4 (3–6) 4 (3–8) 4 (3–6)
Long distance to clinic; 𝑛 (%) 77 (61.1) 10 (52.6) 67 (62.6)
Visits noticed by friends/school; 𝑛 (%) 41 (32.5) 7 (36.8) 34 (31.8)
Caregiver is elderly; 𝑛 (%) 40 (31.7) 10 (52.6) 30 (28.0)
Transport fee is expensive; 𝑛 (%) 40 (31.7) 7 (36.8) 33 (30.8)
Long waiting queues at clinic; 𝑛 (%) 39 (31.0) 6 (31.6) 33 (30.8)
Visits noticed by family/community; 𝑛 (%) 28 (22.2) 6 (31.6) 22 (20.6)
Treatment fatigue; 𝑛 (%) 27 (21.4) 2 (10.5) 25 (23.4)
Having problems taking ART; 𝑛 (%) 24 (19.0) 3 (15.8) 21 (19.6)
Inconvenient clinic operating hours; 𝑛 (%) 21 (16.7) 0 (0.0) 21 (19.6)
Caregiver financial difficulty; 𝑛 (%) 19 (15.1) 3 (15.8) 16 (15.0)
Not enough time for visits; 𝑛 (%) 18 (14.3) 2 (10.5) 16 (15.0)
No sexual health services; 𝑛 (%) 14 (11.1) 1 (5.3) 13 (12.1)
Caregiver is unsupportive; 𝑛 (%) 13 (10.3) 3 (15.8) 10 (9.3)
Lack of peer support/counselling; 𝑛 (%) 13 (10.3) 5 (26.3) 8 (7.5)
Caregiver changes frequently; 𝑛 (%) 8 (6.3) 1 (5.3) 7 (6.5)
Caregiver is ill and requires care; 𝑛 (%) 8 (6.3) 2 (10.5) 6 (5.6)
Distrust health care workers; 𝑛 (%) 7 (5.6) 1 (5.3) 6 (5.6)
Unfriendly health care workers; 𝑛 (%) 4 (3.2) 3 (15.8) 1 (0.9)
Disinterested in care; 𝑛 (%) 1 (0.8) 0 (0.0) 1 (0.9)
(Table 3). To determine if perceived barriers to care differed
by age group, we stratified the cohort into two categories:
younger adolescents aged 12–17 (Supplementary Table A in
Supplementary Material available online at http://dx.doi.org/
10.1155/2016/4161738) and older adolescents aged 18–20 (Sup-
plementary Table B). In addition, having their mother as
their primary caregiver appeared to decrease the likelihood
of missing a clinic visit after study enrolment (27% versus
42% for 12–17 years old and 39% versus 55% for 18–20 years
old). Also greater proportions of adolescents who felt that
unfriendly health care workers, having problems in taking
the medication, and treatment fatigue were barriers to care
missed a subsequent visit compared to those who did not
agree with those statements.
Lack of services at health care facilities was also noted
by both age groups but the service of importance differed;
younger adolescents were more impacted by lack of peer
support and counseling (57% versus 31% missed visit), while
older adolescents agreeing that lack of sexual health services
could pose a barrier to care were more likely to miss a
subsequent visit (67% versus 47%). Certain potential barriers
only appeared to impact adherence to visits in one group
and not the other. Among younger adolescents, visits to the
clinic being noticed by friends or individuals in the school
community were associated with a higher proportion of sub-
sequent missed visits compared to adolescents not perceiving
that as a barrier to care (46% versus 27%), as was agreeing that
difficulty finding time to attend visits and expensive trans-
port fees. For older adolescents, however, agreeing with the
statement that having an ill caregiver who requires care (67%
versus 47%) or a caregiverwith financial difficulty (71% versus
43%) was barriers to care was more common among those
who subsequentlymissed a clinic visit compared to thosewho
did not agree with those factors as potential barriers.
4. Discussion
As pediatric ART has scaled up, HIV care services, mostly
delivered in secondary-level health care facilities, are becom-
ing heavily overburdened, while increasing numbers of chil-
dren are transitioning to adolescence [5]. This is further
complicated by the need for skilled health careworkers able to
manage drug toxicities and psychosocial issues as well as the
higher risk of drug resistance whichmay result from frequent
changing of fixed-dose combinations and/or drug stock-outs
and lower rates of adherence to medication [32–34].
Few studies have assessed treatment outcomes in older
children and/or adolescents in this region, and those that
have report disproportionately poor ART outcomes in this
group compared to adults. A study investigating treatment
outcomes in adolescents (9–19 years) accessing care from a
community-based ART program within a periurban town-
ship in Cape Town, South Africa, showed that adoles-
cents had significantly lower rates of virologic suppression
(<400 copies/mL) (27.3%) compared to young adults (63.1%)
[26]. High rates of mortality and loss to follow-up (LTFU)
have also been reported among adolescents compared to
adults accessing care from primary health care centers [22,
24, 26, 35]. A recent study investigating outcomes in multiple
HIV cohorts fromGauteng andMpumalanga in South Africa
6 AIDS Research and Treatment
Table 3: Factors associated with having at least one late or missed visit (𝑛 = 124).
Characteristic 𝑁 (%) with missed visit Crude risk ratio (95% CI) Adjusted risk ratio∗ (95% CI)
Baseline and demographic factors
Gender
Female 27 (39.1) 1.00 1.00
Male 20 (36.4) 0.93 (0.59–1.47) 1.27 (0.76–2.12)
Age group
12–14 years 15 (28.3) 1.00 1.00
15–17 years 14 (41.2) 1.45 (0.81–2.62) 1.80 (0.94–3.43)
18–20 years 18 (48.6) 1.72 (1.00–2.95) 2.62 (0.89–7.67)
Highest school level
Secondary 21 (44.7) 1.00 1.00
Primary 22 (32.8) 0.73 (0.46–1.17) 1.37 (0.69–2.72)
Dwelling type
Formal 36 (38.3) 1.00 1.00
Care facility 5 (38.5) 1.00 (0.48–2.09) 0.82 (0.40–1.70)
Informal 6 (35.3) 0.92 (0.46–1.84) 1.41 (0.65–3.09)
Mother as caregiver
No 27 (45.8) 1.00 1.00
Yes 20 (30.8) 0.67 (0.43–1.06) 0.66 (0.43–1.03)
Caregiver employed
No 10 (30.3) 1.00 1.00
Yes 32 (40.5) 1.34 (0.75–2.39) 1.40 (0.79–2.48)
Time on ART
<6 years 24 (40.0) 1.00 1.00
>6 years 23 (35.9) 0.90 (0.57–1.41) 0.98 (0.42–2.29)
Caregiver-related factors
Caregiver changes frequently
No 45 (38.8) 1.00 1.00
Yes 2 (25.0) 0.64 (0.19–2.19) 0.57 (0.17–1.88)
Caregiver is elderly
No 30 (35.7) 1.00 1.00
Yes 17 (42.5) 1.19 (0.75–1.89) 1.00 (0.63–1.60)
Caregiver is ill, requires care
No 44 (37.9) 1.00 1.00
Yes 3 (37.5) 0.99 (0.39–2.49) 0.94 (0.37–2.38)
Caregiver is unsupportive
No 42 (37.8) 1.00 1.00
Yes 5 (38.5) 1.02 (0.49–2.10) 0.82 (0.41–1.66)
Caregiver financial difficulty
No 38 (36.2) 1.00 1.00
Yes 9 (47.4) 1.31 (0.76–2.24) 1.29 (0.79–2.09)
Travel-related factors
Long distance to clinic
No 19 (40.4) 1.00 1.00
Yes 28 (36.4) 0.90 (0.57–1.42) 1.00 (0.61–1.64)
Transport fee is expensive
No 30 (35.7) 1.00 1.00
Yes 17 (42.5) 1.19 (0.75–1.89) 1.30 (0.79–2.13)
Not enough time for visits
No 38 (35.5) 1.00 1.00
Yes 9 (52.9) 1.49 (0.89–2.50) 1.27 (0.78–2.09)
AIDS Research and Treatment 7
Table 3: Continued.
Characteristic 𝑁 (%) with missed visit Crude risk ratio (95% CI) Adjusted risk ratio∗ (95% CI)
Psychosocial factors
Visits noticed by community
No 38 (39.2) 1.00 1.00
Yes 9 (33.3) 0.85 (0.47–1.53) 0.75 (0.41–1.39)
Visits noticed by school/peer
No 29 (34.5) 1.00 1.00
Yes 18 (45.0) 1.30 (0.83–2.05) 1.21 (0.76–1.93)
Distrust health care workers
No 45 (38.5) 1.00 1.00
Yes 2 (28.6) 0.74 (0.23–2.45) 0.84 (0.25–2.76)
Disclose status to family
No 3 (50.0) 1.00 1.00
Yes 44 (37.9) 0.76 (0.33–1.75) 0.62 (0.26–1.50)
Disclose status to school/peer
No 34 (41.0) 1.00 1.00
Yes 13 (32.5) 0.79 (0.47–1.33) 0.66 (0.40–1.09)
Health care facility factors
Long waiting queues at clinic
No 38 (43.7) 1.00 1.00
Yes 9 (24.3) 0.56 (0.30–1.03) 0.54 (0.30–0.99)
Inconvenient clinic hours
No 38 (36.9) 1.00 1.00
Yes 9 (42.9) 1.16 (0.67–2.02) 1.20 (0.70–2.05)
Unfriendly health care workers
No 44 (36.7) 1.00 1.00
Yes 3 (75.0) 2.05 (1.11–3.77) 1.61 (0.81–3.17)
No sexual health services
No 41 (37.3) 1.00 1.00
Yes 6 (42.9) 1.15 (0.60–2.21) 1.26 (0.69–2.30)
Lack of peer support
No 41 (36.9) 1.00 1.00
Yes 6 (46.2) 1.25 (0.66–2.36) 0.93 (0.48–1.82)
Treatment-related factors
Having problems taking ART
No 33 (33.0) 1.00 1.00
Yes 14 (58.3) 1.77 (1.14–2.74) 1.45 (0.91–2.32)
Treatment fatigue
No 32 (32.7) 1.00 1.00
Yes 15 (57.7) 1.77 (1.14–2.73) 1.47 (0.94–2.31)
∗Risk ratios individually adjusted for age, gender, mother as caregiver, and time on ART.
found that attrition in ART care occurred soon after the
commencement of ART; the median time to death or loss
to care was 4.7 months (IQR: 1.5–13.2) and 10.9 months
(IQR: 5.0–22.7), respectively. Adolescents were more likely
to be LTFU after ART initiation (hazard ratio (HR) = 1.38;
95% CI: 1.07–1.78) compared to adults, though little age
difference in mortality was found [25]. Despite this clear
indication of increased risk for poor treatment outcomes
among adolescents, the potential causes of poor adherence to
treatment are yet to be clearly identified.
We interviewed a group of 126 adolescents and aimed
to uncover what factors adolescents perceived to be barriers
to accessing and remaining in care. Further, we estimated
associations between agreeing that a factor was a barrier
to care and subsequently missing a scheduled HIV clinic
visit and whether these differed between older and younger
adolescents. We found that the most frequently reported
perceived barriers to carewere related to logistics of the actual
clinic visit: time and cost involved in getting to the visit as
well as duration of time spent waiting in queues. Treatment
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Table 4: Factors associated with prevalent virologic failure among adolescents with a recorded VL measurement (𝑛 = 103).
Variable 𝑛 (%) with prevalent VL failure Crude risk ratio (95% CI) Adjusted∗risk ratio (95% CI)
Baseline and demographic factors
Gender
Female 16 (27.1%) 1.00 1.00
Male 16 (36.4%) 1.54 (0.66–3.56) 1.44 (0.76–2.73)
Age group (years)
12–14 11 (25.6%) 1.00 1.00
15–17 11 (37.9%) 1.78 (0.64–4.91) 2.67 (0.76–9.34)
18–20 10 (32.3%) 1.39 (0.50–3.83) 2.77 (0.51–14.96)
Highest school level
Secondary 14 (35.0%) 1.00 1.00
Primary 14 (25.9%) 0.65 (0.27–1.58) 1.17 (0.28–4.79)
Dwelling type
Formal 26 (32.9%) 1.00 —
Care facility 1 (9.1%) 0.20 (0.02–1.68) —
Informal 5 (38.5%) 1.27 (0.38–4.28) —
Mother caregiver
No 15 (31.3%) 1.00 —
Yes 17 (30.9%) 0.98 (0.43–2.27) —
Caregiver employed
No 10 (35.7%) 1.00 —
Yes 21 (32.3%) 0.86 (0.34–2.18) —
Caregiver-related factors
Caregiver changes frequently
No 32 (32.7%) 1.00 —
Yes 0 (0.0%) — —
Caregiver is elderly
No 22 (30.6%) 1.00 1.00
Yes 10 (32.3%) 1.08 (0.44–2.67) 1.31 (0.69–2.48)
Caregiver is ill, requires care
No 29 (29.9%) 1.00 1.00
Yes 3 (50.0%) 2.34 (0.45–12.31) 0.65 (0.09–4.55)
Caregiver is unsupportive
No 28 (30.8%) 1.00 —
Yes 4 (33.3%) 1.13 (0.31–4.05) —
Caregiver financial difficulty
No 26 (30.2%) 1.00 1.00
Yes 6 (35.3%) 1.26 (0.42–3.77) 2.51 (0.51–12.38)
Travel-related factors
Long distance to clinic
No 11 (28.2%) 1.00 1.00
Yes 21 (32.8%) 1.24 (0.52–2.97) 0.43 (0.18–1.04)
Transport fee is expensive
No 20 (27.8%) 1.00 1.00
Yes 12 (38.7%) 1.64 (0.68–3.99) 1.79 (0.76–4.19)
Not enough time for visits
No 28 (31.1%) 1.00 —
Yes 4 (30.8%) 0.98 (0.28–3.47) —
Psychosocial factors
Visits noticed by community
No 32.9% (26) 1.00 1.00
Yes 25.0% (6) 0.68 (0.24–1.92) 0.37 (0.15–0.93)
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Table 4: Continued.
Variable 𝑛 (%) with prevalent VL failure Crude risk ratio (95% CI) Adjusted∗risk ratio (95% CI)
Visits noticed by school/peer
No 31.4% (22) 1.00 1.00
Yes 30.3% (10) 0.95 (0.39–2.33) 1.02 (0.44–2.37)
Distrust health care workers
No 30.3% (30) 1.00 1.00
Yes 50.0% (2) 2.30 (0.31–17.10) 6.15 (1.14–33.24)
Disclose status to family
No 33.3% (1) 1.00 1.00
Yes 31.3% (31) 0.91 (0.08–10.44) 1.34 (0.39–4.63)
Disclose status to school/peer
No 34.3% (24) 1.00 1.00
Yes 25.0% (8) 0.64 (0.25-1.64) 0.51 (0.20–1.26)
Health care facility factors
Long waiting queues at clinic
No 27 (35.5%) 1.00 1.00
Yes 5 (18.5%) 0.41 (0.14–1.21) 0.94 (0.28–3.12)
Inconvenient clinic operating hours
No 28 (32.6%) 1.00 1.00
Yes 4 (23.5%) 0.64 (0.19–2.13) 0.49 (0.16–1.52)
Unfriendly health care workers
No 32 (31.4%) 1.00 —
Yes 0 (0.0%) — —
No sexual health services
No 28 (31.1%) 1.00 1.00
Yes 4 (30.8%) 0.98 (0.28–3.47) 0.70 (0.19–2.50)
Lack of peer support
No 31 (33.0%) 1.00 —
Yes 1 (11.1%) 0.25 (0.03–2.12) —
Treatment-related factors
Having problems taking ART
No 26 (31.3%) 1.00 1.00
Yes 6 (30.0%) 0.94 (0.32–2.72) 0.36 (0.16–0.82)
Treatment fatigue
No 23 (28.4%) 1.00 1.00
Yes 9 (40.9%) 1.75 (0.66–4.64) 1.71 (0.78–3.75)
∗Risk ratios individually adjusted for age, gender, mother as caregiver, and time on ART.
programs requiring patients to return to the clinic more
frequently or travel longer distances to receive necessary
drugs increase the economic burden of transport costs and
the possibility of lost wages for patients, both of which are
well known barriers of adherence to HIV care and treatment
[13, 14].Though our samplewas restricted to an urban setting,
previous research has also shown that the type of community
(urban versus rural) can be a factor of adherence to HIV care
and treatment due to differences in community characteris-
tics such as density of population, distance to and availability
of clinics and hospitals, and infrastructure within clinics [36,
37]. Reassuringly, very few considered not being interested
in treatment, unfriendly health care workers, or distrust of
health care workers as important potential barriers to care,
though it must be considered that adolescent experiencing
these barriers personally may not be attending visits at all.
We also found that older adolescents appear to be a
key subgroup of this already vulnerable population; older
adolescents were at increased risk formissing a clinic visit and
were also more likely to have experienced prevalent virologic
failure at the time of study enrolment compared to younger
age categories.This has been demonstrated elsewhere [24, 25,
38, 39] and understanding drivers of poor adherence in this
group is critical. One possibility is simply that younger age
groups represent perinatally infected children who represent
a groupwho have been on treatment for longer period of time
and are more likely to be adherent to treatment. However, the
reality for many adolescents accessing care in this setting is
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that attending a clinic visit may take up a full day requiring
time off school as well as time away from other household
and family responsibilities. The impact of this time pressure
does appear to differ between older and younger adolescents.
We note that older adolescents more frequently agreed that
having an elderly caregiver presented a potential barrier to
care (47%) compared to younger adolescents (33%). This
may reflect social circumstances where, as adolescent ages,
increased responsibilities for caring for elderly members of
the family are placed on them, inwhich, alongwith increasing
demands during more senior years at school or entry into
the workforce, time away from school/work and home
responsibilities may represent a substantial obstacle in this
group. While having problems in taking the medication and
treatment fatigue were identified as barriers in both younger
and older adolescents who missed a visit, the proportion of
older adolescents that identified unfriendly health care work-
ers as a barrier was far greater (RR: 2.19; 95% CI: 1.52–3.14,
Table 3). Though the numbers represented are too small to
make strong inferences, differences in provider relationships
between adult-based and pediatric-based facilities could be
important andmodifiable factors affecting adherence to care.
Having problems taking ART (most frequently reported
as forgetting to take the medication) was identified as one of
the treatment-related barriers to care by both age groups of
adolescents and was associated with an increased risk of poor
adherence to visits. Several interventions have been tested for
feasibility and efficacy in terms of reminders to take tablets
and may present an opportunity to improve a relatively easily
modifiable risk factor for poor adherence among adolescents.
These includemobile phone textmessage reminders and elec-
tronic medication monitoring devices [40, 41]. Though ado-
lescents frequently agreed that treatment fatigue was a poten-
tial barrier to accessing and remaining in care and those who
agreed with this statement were more likely to subsequently
miss a visit (58% versus 33%), there was little difference in the
likelihood ofmissing visits by time onART (40% and 36% for
those on ART < 6 years and > 6 years, resp.). It is possible that
attrition due to treatment fatigue occurs earlier on and the
group that would be susceptible to dropping out of care due
to treatment fatigue is not accurately represented in this study.
Disclosure of HIV status is an important issue in adoles-
cent populations: not only disclosure of status to the vertically
infected child but also disclosure by the adolescents them-
selves to family, friends, and members of their school and
community. Among the group of adolescents interviewed,
>95% agreed that disclosing status to family would facilitate
access to care, but only a third agreed that disclosing to school
and friends would be of assistance. In fact, one of the most
frequently perceived barriers to care was the fact that the
frequency of HIV clinic visits would be noticed by friends
or members of the school community and among the group
aged 12–17; perceiving this factor as a barrier to care was
associated with a 70% increased risk of subsequently missing
a clinic visit, underlining the social challenges and stigma that
school-going adolescents face while in ART care programs.
Our findings must be considered in light of some limita-
tions. First, we acknowledge that, by definition, all the partic-
ipants interviewed were still accessing care at the time of the
study and the factors identified by this group as important
determinants of accessing and staying in care may differ
from those that would potentially be identified by adolescents
who have already dropped out of care. Second, the small
numbers enrolled limited the statistical power to detect small
differences and precision of our estimates. However, the
analysis presented here aimed to explore possible associations
between the factors investigated and adherence to ART treat-
ment rather than establishing causal associations and should
be interpreted as such. Third, we were unable to enroll some
participants <18 years of age (9% of the total screened partic-
ipants) due to the fact that a legal guardian was not able to be
present to sign consent. If those who were not enrolled dif-
fered systematically from those <18 years that consented, this
could result in selection bias. In addition, bias may arise if the
need for caregiver consent to participate in the study influ-
enced the responses provided by the adolescents interviewed.
Thoughwe cannot rule this possibility out completely, several
steps were taken during the consenting and interviewing
process to prevent this, including an explanation of the
procedures undertaken to ensure confidentiality and con-
ducting the interview in a private space. Finally, we did not
measure depression or stigma directly as potential barriers to
care and these may contribute significantly to the perception
of other factors.
5. Conclusions
Despite these limitations, our study results are important.
First, we demonstrate the increased risk of poor adherence
to care for older adolescents, highlighting this group as a
key population for intervention if 90-90-90 targets are to
be met. In addition, we report on several modifiable factors
that may be barriers to accessing and remaining in care
among adolescents and show that these differ in importance
and impact between older and younger adolescents. Several
different interventions to improve retention in care and
adherence to treatment have been proposed including finan-
cial incentives and behavioral and facility level interventions
such as peer social support and adherence clubs [35, 42–46].
Evaluation of the effectiveness and potential impact of dif-
ferent intervention approaches is needed within the context
of each of the progressive stages of adolescence. Adherence to
ART is complex, and amultifaceted approach acknowledging
changing barriers to accessing and remaining in care is
requiredwhen designing and implementing interventions for
adolescent populations.
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